Types
- Adenocarcinoma — nearly all prostate cancers1.
- By risk group: low-risk cancers that may never cause harm, intermediate-risk, high-risk, and metastatic disease1.
- Castration-sensitive vs. castration-resistant — whether advanced cancer still responds to lowering testosterone1.
- Rare types include neuroendocrine (small-cell) prostate cancer1.
Prevention
- There's no proven way to prevent prostate cancer. Screening aims to find dangerous cancers early without overtreating harmless ones2.
- For men 55 to 69, the USPSTF recommends deciding about PSA screening individually after discussing benefits and harms with a clinician; it recommends against routine screening at 70 and older2.
Risk factors
- Older age — the strongest risk factor1
- A father or brother with prostate cancer1
- Black ancestry — higher rates and higher death rates1,2
- Inherited gene variants, especially BRCA24
Diagnostics
- PSA blood test — a screening signal, not a diagnosis; PSA also rises with benign enlargement and inflammation2.
- MRI before biopsy — in the PRECISION trial, MRI-targeted biopsy found more clinically significant cancers (38% vs. 26%) and fewer insignificant ones than standard biopsy3.
- Biopsy graded with the Gleason score, reported as Grade Group 1 to 51.
- Staging scans such as PSMA PET for higher-risk cancer1.
Treatments
- Active surveillance for low-risk cancer: regular PSA tests, MRI, and repeat biopsies, treating only if the cancer progresses1.
- Surgery (radical prostatectomy) or radiation therapy for localized cancer that needs treatment1.
- In the ProtecT trial, about 2–3% of men died of prostate cancer over 15 years whether they had monitoring, surgery, or radiation. Monitoring led to more spread, but not more deaths; surgery and radiation caused more urinary and sexual side effects5.
- Hormone therapy (androgen deprivation) combined with newer drugs for advanced cancer1.
Molecular Biomarkers
- PSA, along with PSA density and free PSA1.
- Blood and urine tests such as the Prostate Health Index (PHI), 4Kscore, and PCA3 help decide who needs a biopsy1.
- Gleason score / Grade Group from biopsy tissue1.
- Tissue genomic tests can refine risk in localized cancer1.
- In advanced cancer, tumors are tested for DNA-repair defects such as BRCA1, BRCA2, and ATM changes, and for mismatch-repair deficiency, which make targeted drugs or immunotherapy an option1,4.
Genes
- About 12% of men with metastatic prostate cancer carry an inherited DNA-repair gene mutation, most often BRCA2, followed by CHEK2, ATM, and BRCA14.
- Germline genetic testing is now recommended for men with metastatic prostate cancer; results also tell relatives about their own cancer risk.
- Variants in HOXB13 also raise risk.
Lifestyle
- No lifestyle change is proven to prevent prostate cancer.
- Staying active and keeping a healthy weight support overall health and help offset side effects of hormone therapy, such as bone and muscle loss.
- Men on active surveillance should keep every scheduled check-up1.
Nutrition
- No diet or supplement is proven to prevent prostate cancer.
- Large trials of selenium and vitamin E supplements found no protective benefit, and vitamin E slightly increased risk.
Medical Interventions
- Radical prostatectomy, usually robot-assisted1
- External-beam radiation or brachytherapy (radioactive seeds)1
- Focal therapies such as high-intensity focused ultrasound in selected cases1
Pharmaceutical Drugs
- Androgen deprivation therapy: leuprolide, goserelin, degarelix, relugolix1
- Androgen receptor pathway inhibitors: abiraterone, enzalutamide, apalutamide, darolutamide1
- Chemotherapy: docetaxel, cabazitaxel1
- PARP inhibitors: olaparib, rucaparib for cancers with DNA-repair defects1,4
- Radioligand therapy: lutetium-177 PSMA-617 for PSMA-positive metastatic castration-resistant cancer
- Bone-targeted therapy: radium-223, denosumab, zoledronic acid1
- Immunotherapy: pembrolizumab for mismatch-repair–deficient tumors1
Sources
- Rebello RJ, Oing C, Knudsen KE, et al. Prostate cancer. Nat Rev Dis Primers. 2021;7(1):9. doi:10.1038/s41572-020-00243-0
- US Preventive Services Task Force; Grossman DC, Curry SJ, et al. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018;319(18):1901-1913. doi:10.1001/jama.2018.3710
- Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018;378(19):1767-1777. doi:10.1056/NEJMoa1801993
- Pritchard CC, Mateo J, Walsh MF, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375(5):443-453. doi:10.1056/NEJMoa1603144
- Hamdy FC, Donovan JL, Lane JA, et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2023;388(17):1547-1558. doi:10.1056/NEJMoa2214122
This page summarizes published research for education. It isn't medical advice and doesn't replace care from a clinician who knows your history. Never start, stop, or change a medication without talking to your prescriber.